AOD9604

Batch #513210Batch #513210
Report #53442Report #53442
Tested at 2.4mgTested at 2.4mg
Size: 1.5mg
Visa Mastercard American Express Discover Apple Pay Google Pay
Ships by ...
Flag
FREE Shipping

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About AOD9604

AOD9604 is a synthetic peptide based on a modified fragment of human growth hormone (hGH) specifically the 176-191 segment with an added di-sulfide bridge. It is studied for its potential role in metabolic research.

Product Specifications

AOD-9604 Lyophilized Powder in 3ml vial.

Application

Nitric oxide synthase generation simulator

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C78H123N23O23S2

PubChem CID

71300630

CAS Number

386264-39-7

Molecular Weight

1815.12 g/mol

Synonyms

AOD 9604, AOD-9604, AOD9604, somatostatin (177-191), Tyr-, somatostatin (177-191), tyrosyl-, Tyr-somatostatin (177-191)

Storage

Store at ≤6°C, sealed, away from heat, light and moisture.

AOD9604 Research

1. AOD9604 and Fat Metabolism 

AOD9604 is a modified peptide fragment derived from human growth hormone (HGH), specifically from the C-terminal region (amino acids 177–191). It was created to reduce body fat percentage without interfering with the natural insulin levels. Studies demonstrate that AOD9604 functions in stimulating the breaking down of fat (lipolysis) and prevent formation of new fat cells (lipogenesis).

According to a research, AOD9604 has been shown to stimulate the reduction of body fat specifically to the area of stubborn fat deposits (in particular abdominal fat) without any adverse affects to lean body mass. Unlike the full length growth hormone, AOD9604 seems to not stimulate IGF-1 which is the major factor that brings about growth related unwanted side effects.

 

2. Mechanism of Action 

AOD9604 supports the burning of fat through adapting the fat-loss effects of growth hormone, but unlike HGH it does not promote unnecessary bone or other organs' growth, making it a much safer alternative. It works by stimulating body fat cells receptor known as adipose tissue that break down stored fat and release them into the bloodstream for use as energy.

Research has also shown AOD9604 to stimulate lipolysis (the breakdown or destruction of fat) and energy use, which can support the loss of excess body fat even without doing drastic changes to your diet and exercise habits. Because it acts only with fat tissue receptors, it is believed to be a safer and more specific alternative to conventional growth hormone therapies.

 

3. Clinical Research and Findings 

Some of the human studies have been conducted on AOD9604 regarding its safety and metabolic effects. One of the clinical studies was performed in 300 obese adults and they received orally AOD 9604 (at doses from 0.25 mg to 1 mg daily) or placebo during a period of 12 weeks. This was a randomized, double-blind, placebo-controlled trial.

Results showed that participants taking AOD9604 experienced a modest but measurable reduction in body fat, averaging around 2.6 kg more fat loss compared to 0.8 kg in the placebo group. Importantly, AOD9604 was found to be safe and well-tolerated, with no significant changes in blood sugar, insulin, or IGF-1 levels.

Over time, these results indicate that although AOD9604 may not cause much substantial weight loss, but it promotes healthy fat loss while avoiding the negative hormonal reactions associated with standard growth hormone therapy.

 

4. Safety and Tolerability 

AOD9604 is safe for human use according to clinical data. In all studies there were no negative effects that are related to the growth hormone activity. For example regulating the blood glucose, insulin sensitivity, or unneccessary growth of organs.

The most common mild side effects were headache, mild fatigue or irritation at the injection site (if injected subcutaneously). These were very minor and be deal with instantly. AOD9604 was accepted for long-term use, with an excellent safety profile and good tolerability at all doses tested.

 

5. Pharmacokinetics and Administration 

AOD9604 can either be taken in the oral form or through subcutaneous injection (depending on the preparation). It has a short plasma half-life, but action is mediated through receptor pathways that impact fat metabolism for hours after getting into the body.

The usual dosage used in research studies ranged from 0.25 mg to 1 mg per day, administered over several weeks. It’s stability, safety, and little to low hormonal side effect making it to be a promising option for further investigation in support of weight management and metabolic health.

 


Source: Safety and pharmacokinetics of AOD9604 in humans (Herington et al., 2013).

You ask,
we answer.